Pfizer Inc.
NYSEPfizer delivered a Q1 beat but the stock ended the week almost flat — and short sellers spent the week adding to positions at a pace that has been building steadily since early April. Short interest is the story that stands out this week, even if the absolute level remains modest. SI climbed to 2.53% of the free float on May 5, up from 2.13% at the start of April — a 19% rise in the…
Snapshot as of 6 May 2026
A new long-form analysis for PFE this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumPfizer delivered a Q1 beat but the stock ended the week almost flat — and short sellers spent the week adding to positions at a pace that has been building steadily since early April. Short interest is the story that…
Pfizer heads into its May 5 Q1 results with the Street still deeply divided — and a stock price that has done little to resolve the argument. The options market is not sending a strong directional signal ahead of the…
Short sellers have raised bearish bets on PFE by 14% over the past month. Analyst opinion remains split, with targets averaging 7% upside but recent downgrades tempering optimism. Short interest stands at 136.8 million…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PFE — free to start on ORTEX.
Sign up for free →Open PFE on ORTEX